viewAcasti Pharma Inc

Full interview: Acasti has 'put its finger on something very interesting' in new data, updates on TRILOGY trial

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of the year. 

What's more, Lemieux talked about  how the company has 'put its finger on something very interesting' referencing recent pre-clinical data that indicates Acasti may be able to enter the diabetes space

Quick facts: Acasti Pharma Inc

Price: 0.77 CAD

Market: TSX-V
Market Cap: $74.61 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...


Full interview: Acasti Pharma signs long term deal with Aker Bio Marine to...

Acasti Pharma  (CVE: ACST) Chief Operations and Scientific Officer Pierre Lemieux joined Steve Darling to discuss the company signing a long term deal to a have a consistent supply of the Krill Oil which is critical in the development of their flagship product CaPre. Lemieux discussing...

on 5/11/19

2 min read